Top 10 States for Physician-Owned Hospitals - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Top 10 States for Physician-Owned Hospitals

These 10 states make it more practical for physicians to participate in hospital ownership by aligning statutory structure, corporate practice of medicine rules, and population trends.

  • By

  • mdspire news news staff

  • May 1, 2026

  • 3 min

Share

Objective:

To outline the regulatory environment for physician-owned hospitals across various states in the U.S.

Key Findings:
  • Physician ownership is regulated by both federal and state laws.
  • Each state has specific statutes governing the practice of medicine and physician licensure, which can impact ownership opportunities.
  • Population demographics and growth rates vary significantly across states, influencing the regulatory environment.
Interpretation:

The regulatory landscape for physician-owned hospitals is complex and varies by state, impacting physician participation and ownership opportunities.

Limitations:
  • The article does not provide detailed comparisons of the regulatory frameworks across states.
  • Population data may not reflect current trends post-2020.
  • Lack of detailed state comparisons limits understanding of the regulatory landscape.
Conclusion:

Understanding both federal and state-specific regulations is crucial for physicians considering ownership of hospitals.

Sources:

Original Source(s)

Top 10 States for Physician-Owned Hospitals

  • by mdspire news news staff

  • May 1, 2026

Related Content

Low IMA Ligation Did Not Significantly Reduce Leaks

A randomized trial found similar short-term morbidity and 12-month functional outcomes with both approaches, while highlighting the need to balance perfusion with a tension-free anastomosis.

Can Endotoxin-Targeted Care Improve Sepsis Outcomes?

Biomarker-guided patient selection may help identify patients with sepsis who could benefit from endotoxin-targeted therapy, although confirmatory evidence is still needed.

Oral Aleniglipron Reduced Weight at 36 Weeks

In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.